MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2023

“The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6 months”October – December Financial summary for the quarter · Net turnover amounted to SEK 4.4 (2.3) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -20.1(-17.9) million. Basic and diluted earnings per share amounted to SEK -0.28 (-0.32) and SEK -0.28 (-0.32) respectively. · Cash flow from operating activities amounted to SEK -4.6 (-24.7) million. · Cash and cash equivalents at the